Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: A case report
Abstract Women taking entecavir hydrate (ETV) may not need to consider abortion in the event of an unexpected pregnancy. If a woman with renal dysfunction and taking ETV for chronic hepatitis B becomes pregnant, continuous use of ETV may also be tolerated.
Main Authors: | Toshihiko Kakiuchi, Hirokazu Takahashi, Shinji Iwane, Azusa Koji, Muneaki Matsuo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.3896 |
Similar Items
-
Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024-02-01) -
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial
by: Wei Peng, et al.
Published: (2023-12-01) -
Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial
by: Li-Xin Pan, et al.
Published: (2024-01-01) -
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Ming-Chao Tsai, et al.
Published: (2021-09-01) -
Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
by: Zili Hu, et al.
Published: (2022-03-01)